While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. Estimate Revisions Trend Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) ...

YCharts % Loss/Gain BKH is $2.42 over-priced, SWK is $24.34 overpriced, and FRT needs to lose $34.59 in price to join the ideal eight. 42% Irina Nedikova/iStock via Getty Images As a supplement to this article, please note that The Motley Fool, which sourced this latest list, and SureDividend both update their lists periodically. any) of these Kings show "safe" dividends (with sufficient cash reserves to cover their payout), click on the last bullet point at the top 0 the article after July 18. Estimated di ...

Overview KVUE's currently dividend yield sits at a solid starting point of 4.3%. While KVUE hasrit been listed long enough to have established any sort of dividend growth yet, I do believe that it has the potential to eventually grow into a dividend compounder once market conditions improve. KVUE went public during a time of high inflation, lower consumer spend, and a decade high-interest rates, so to its credit, the stock hasn't really had a chance to prove itself yet. KVUE reported their Q1 earnings at th ...

It's a great time to be looking at healthcare stocks to buy now. According to research from BlackRock, U.S. healthcare stocks have outperformed the overall stock market by an average of 10% over the past seven recessions. Given high interest rates, inflation and the possibility of an economic slowdown in coming months, it could be a great time for defensive investment categories such as healthcare. More broadly, the sector should enjoy several positive factors in coming years. For one, there is demographics ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-41697 Kenvue Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 19 ...

Kenvue Inc. (NYSE:KVUE) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Tina Romani - Investor Relations Thibaut Mongon - Chief Executive Officer Paul Ruh - Chief Financial Officer Conference Call Participants Andrea Teixeira - J.P. Morgan Bonnie Herzog - Goldman Sachs Stephen Powers - Deutsche Bank Nik Modi - RBC Capital Markets Anna Lizzul - Bank of America Securities Filippo Falorni - Citigroup Korinne Wolfmeyer - Piper Sandler Operator Hello and welcome to Kenvue First Quart ...

Kenvue Reports First Quarter 2024 Results Q1'24: Net Sales Increased 1.1% to $3.9 Billion with Organic Growth of 1.9% 1 Q1'24: Diluted Earnings per Share of $0.15; Adjusted Diluted Earnings per Share of $0.28 1 Reaffirms Fiscal Year 2024 Outlook SKILLMAN, N.J. May 7, 2024 – Kenvue Inc. (NYSE: KVUE) ("Kenvue"), today announced financial results for the fiscal first quarter ended March 31, 2024. "We entered 2024 with clear strategic priorities to reach more consumers, reinvent our ways of working to invest mo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-41697 Kenvue Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 199 Gra ...

Financial Data and Key Metrics Changes - In 2023, net sales grew 3.3% to $15.4 billion, with organic growth of 5% reflecting a value realization of 7.7% and a volume decrease of 2.7% [29][60] - Fourth quarter organic sales declined 2.4%, contrasting with 6.2% organic growth in the previous year [27][29] - Fourth quarter gross margin expanded 220 basis points to 59.5%, while full-year adjusted gross margin increased 30 basis points to 58.4% [58][59] Business Line Data and Key Metrics Changes - Essential Health segment achieved 3.6% organic growth, exceeding long-term expectations, driven by gross margin enhancement strategies [9][10] - Self Care, the largest segment, delivered organic growth of 8.4% in 2023, following 10.9% growth in 2022 [16][37] - Skin Health and Beauty segment experienced organic growth of 1.8%, below expectations due to in-store execution issues in the US [38][41] Market Data and Key Metrics Changes - EMEA and Latin America showed strong performance, with double-digit growth in Latin America driven by Neutrogena's successful product launches [12][40] - In China, weaker consumer demand negatively impacted skin care brands, particularly Dr.Ci:Labo, due to temporary PR issues [41][104] - The US market underperformed expectations, with a disappointing execution of recovery plans in the Skin Health and Beauty segment [41][82] Company Strategy and Development Direction - The company has identified three key priorities for 2024: reaching more consumers, investing in brands, and fostering a performance-driven culture [7][50][98] - Plans include enhancing in-store presence, amplifying consumer engagement, and increasing marketing investments by approximately 15% [21][65][118] - The company aims to stabilize the Skin Health and Beauty business in the US while monitoring consumer sentiment in China [49][127] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the Skin Health and Beauty segment but expressed confidence in the plans to improve execution and stabilize the business [55][72] - The outlook for 2024 anticipates organic growth in the range of 2% to 4%, with expectations for sequential improvement throughout the year [64][90] - Management highlighted potential headwinds, including softness in China and ongoing in-store execution issues in the US [92][102] Other Important Information - The company generated $2.7 billion in free cash flow for the year, benefiting from separation-related items and working capital timing [32][61] - A dividend program was initiated, reflecting a commitment to returning cash to shareholders with a 64% payout ratio [39][61] - Adjusted diluted earnings per share were $0.31 for the quarter and $1.29 for the year, including a benefit from non-recurring items [88][96] Q&A Session Summary Question: What is the visibility on the organic forecast for 2024? - Management expressed confidence in the organic growth forecast, expecting sequential improvement as investments and strategic initiatives take effect [100][101] Question: Can you clarify the advertising spend and its impact? - Advertising spend was slightly down in 2023, primarily due to reduced investment in Asia-Pacific, but plans for a 15% increase in 2024 were confirmed [139][142] Question: What are the specific challenges in the Skin Health and Beauty segment? - The challenges are mainly attributed to weak demand in China and in-store execution issues in the US, with a focused plan to improve these areas [104][143]

Financial Performance - Kenvue's full year 2023 net sales reached $15.4 billion[25], with organic growth of 5.0%[47] - The adjusted gross profit margin for full year 2023 was 58.4%[91], compared to a reported gross profit margin of 56.0%[91] - Full year 2023 adjusted diluted earnings per share was $1.29[258] - The company's Q4 2023 net sales were $3.8 billion[45], a 5.8% increase[45], with organic growth of 7.7%[88] - Adjusted operating income margin for Q4 2023 was 21.8%[94], while the reported operating income margin was 12.5%[95] Segment Performance - Self Care net sales for the fiscal year 2023 were $6.451 billion[13] - Skin Health and Beauty net sales for the fiscal year 2023 were $4.378 billion[17] - Essential Health net sales for the fiscal year 2023 were $4.615 billion[20] 2024 Outlook - Kenvue projects full year 2024 reported net sales growth of 1.0% - 3.0%[170] and organic growth of 2.0% - 4.0%[170] - The company anticipates a full year 2024 adjusted diluted earnings per share of $1.10 - $1.20[170], assuming a diluted weighted average share count of 1.92 billion[171]